Valuation
- Market cap
- 118,374,000
- Revenue TTM
- $0
- Net income TTM
- $-78,540,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 835,400
- Avg volume
- 832,596
- Day's range
- $6.06 – $6.68
- Shares out
- 18,671,000
- Stochastic %K
- 4%
- Beta
- 2.63
- Analysts
- Strong Sell
- Price target
- $35.89
Company profile
Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. The...
Show more
Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. The company was incorporated in 2009 and is headquartered in Norwood, Massachusetts.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 617 963 0100
- Website
- https://www.corbuspharma.com
- Address
- 500 River Ridge Drive, Norwood, United States
Latest news
No headlines yet.
